keyword
MENU ▼
Read by QxMD icon Read
search

docetaxel

keyword
https://www.readbyqxmd.com/read/29666962/activity-of-indatuximab-ravtansine-against-triple-negative-breast-cancer-in-preclinical-tumor-models
#1
Kurt Schönfeld, Peter Herbener, Chantal Zuber, Thomas Häder, Katrin Bernöster, Christoph Uherek, Jörg Schüttrumpf
PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cells and has previously shown clinical activity in multiple myeloma. Here we show indatuximab ravtansine as a potential mono- and combination therapy for TNBC. METHODS: The effects of indatuximab ravtansine were assessed in vitro in SK-BR-3 and T47D breast cancer cell lines...
April 17, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29666858/polytyrosine-nanoparticles-enable-ultra-high-loading-of-doxorubicin-and-rapid-enzyme-responsive-drug-release
#2
Xiaolei Gu, Min Qiu, Huanli Sun, Jian Zhang, Liang Cheng, Chao Deng, Zhiyuan Zhong
Despite the great significance of clinically viable nanovehicles, very few of them exhibit stability and high anticancer drug loading with fast intracellular drug release. Herein, we report that polytyrosine nanoparticles (PTNs) self-assembled from poly(ethylene glycol)-b-poly(l-tyrosine) block copolymer enable the ultra-high loading and rapid enzyme-responsive release of doxorubicin (DOX). Notably, PTNs achieve a remarkably high DOX loading of 63.1 wt% likely due to the existence of strong π-π stacking between polytyrosine and DOX, as shown by UV-vis analysis...
April 18, 2018: Biomaterials Science
https://www.readbyqxmd.com/read/29666302/targeting-galectin-1-impairs-castration-resistant-prostate-cancer-progression-and-invasion
#3
Tsung-Chieh Shih, Ruiwu Liu, Chun-Te Wu, Xiaocen Li, Wenwu Xiao, Xiaojun Deng, Zsofia Kiss, Ting Wang, Xiaojia Chen, Randy P Carney, Hsing-Jien Kung, Yong Duan, Paramita M Ghosh, Kit S Lam
PURPOSE: The majority of prostate cancer (PCa) patients who are treated with androgen deprivation therapy (ADT) will eventually develop fatal metastatic castration-resistant prostate cancer (mCRPC). Currently, there are no effective durable therapies for patients with mCRPC. High expression of Galectin-1 (Gal-1) is associated with PCa progression and poor clinical outcome. The role of Gal-1 in tumor progression are largely unknown. Here we characterized Gal-1 functions and evaluated the therapeutic effects of a newly developed Gal-1inhibitor, LLS30, in mCRPC...
April 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29665663/-analysis-of-neoadjuvant-docetaxel-carboplatin-and-trastuzumab-tch-in-her-2-positive-breast-cancer
#4
L Xu, J M Ye, S N Zhu, J Y Zhao, L Xin, Y J Cheng, Q Liu, H Zhang, S Zhang, X N Duan, Y H Liu
Objective: To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab (H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. Methods: From January 2008 to December 2014, the data of patients diagnosed as early breast cancer in Breast Disease Center of Peking University First Hospital were retrospective reviewed. The data of patients with HER-2 positive conducted TCH neoadjuvant therapy and surgery, and with the complete clinicopathological information were analyzed...
March 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29665645/microrna-195-regulates-docetaxel-resistance-by-targeting-clusterin-in-prostate-cancer
#5
Xiaokun Ma, Liyuan Zou, Xing Li, Zhanhong Chen, Qu Lin, Xiangyuan Wu
MicroRNAs (miRNAs) have been implicated in neoplasm growth, metastasis, vasculogenesis, and drug resistance. It has been validated that abnormal miR-195 expression was related with poor survival of prostate cancer (PC); however, its role in the resistance to chemotherapeutic drugs docetaxel (DOC) in PC is still acquainted scarcely. In our study, the lower expression of miR-195 was appeared in DOC-resistant PC cells (DU145/DOC) rather than DOC-sensitive DU145 cells. The up-regulation of miR-195 lowered the IC50 of DOC, facilitated the apoptosis and inhibited the colony formation ability in DU145/DOC cells...
March 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29664354/combined-taxane-based-chemotherapy-and-intensity-modulated-radiotherapy-with-simultaneous-integrated-boost-for-gastroesophageal-junction-adenocarcinoma
#6
Corrado Spatola, Alessandra Tocco, Antonio Pagana, Roberto Milazzotto, Raffaele Luigi, Vincenzo Salamone, Carmelo Militello, Marcello Migliore, Pietro Valerio Foti, Antonio Di Cataldo, Grazia Acquaviva, Giuseppe Privitera
We describe our experience, gained over the past 3 years, in the treatment of gastroesophageal junction adenocarcinoma, whose incidence has been increasing in recent years. In our series, we present the results to a follow-up of about 2 years for a total of 18 patients, treated with a particularly intensive combination treatment. It consists of neoadjuvant induction chemotherapy with the protocol docetaxel-cisplatin-5-fluorouracil for four cycles, before a concomitant chemoradiotherapy treatment. During combined phase, patients received an intensity-modulated radiotherapy and a weekly cisplatin...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29663729/hepatitis-b-infection-reported-with-cancer-chemotherapy-analyzing-the-us-fda-adverse-event-reporting-system
#7
Akimasa Sanagawa, Yuji Hotta, Tomoya Kataoka, Yasuhiro Maeda, Masahiro Kondo, Yoshihiro Kawade, Yoshihiro Ogawa, Ryohei Nishikawa, Masahiro Tohkin, Kazunori Kimura
We conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database on spontaneously reported adverse events to evaluate the association between anticancer drug therapy and hepatitis B infection. Reports of hepatitis B infection were retrieved from the FAERS database. The reporting odds ratio (ROR) was used to estimate the association between hepatitis B infection and various anticancer agents and drug combinations. We detected statistically significant risk signals of hepatitis B for 33 of 64 anticancer agents by ROR (26 cytotoxicity drugs and seven molecular-targeted drugs)...
April 16, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29663374/oleic-acid-promotes-prostate-cancer-malignant-phenotype-via-the-g-protein-coupled-receptor-ffa1-gpr40
#8
Antonietta Liotti, Vincenzo Cosimato, Paola Mirra, Gaetano Calì, Domenico Conza, Agnese Secondo, Gelsomina Luongo, Daniela Terracciano, Pietro Formisano, Francesco Beguinot, Luigi Insabato, Luca Ulianich
Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related death in industrialized countries. Epidemiologic evidence suggests that obesity promotes aggressive PCa. Recently, a family of Free Fatty Acid (FFA) receptors (FFARs) has been identified and reported to affect several crucial biological functions of tumor cells such as proliferation, invasiveness, and apoptosis. Here we report that oleic acid (OA), one of the most prevalent FFA in human plasma, increases proliferation of highly malignant PC3 and DU-145 PCa cells...
April 16, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29662002/carotenoid-lutein-selectively-inhibits-breast-cancer-cell-growth-and-potentiates-the-effect-of-chemotherapeutic-agents-through-ros-mediated-mechanisms
#9
Xiaoming Gong, Joshua R Smith, Haley M Swanson, Lewis P Rubin
Increasing evidence suggests that dietary carotenoids may reduce the risk of breast cancer. However, anti-breast cancer effects of carotenoids have been controversial, albeit understudied. Here, we investigated the effects of specific carotenoids on a wide range of breast cancer cell lines, and found that among several carotenoids (including β-carotene, lutein, and astaxanthin), lutein significantly inhibits breast cancer cell growth by inducing cell-cycle arrest and caspase-independent cell death, but it has little effect on the growth of primary mammary epithelial cells (PmECs)...
April 14, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29658567/hepacam-inhibits-the-malignant-behavior-of-castration-resistant-prostate-cancer-cells-by-downregulating-notch-signaling-and-pf-3084014-a-%C3%AE-secretase-inhibitor-partly-reverses-the-resistance-of-refractory-prostate-cancer-to-docetaxel-and-enzalutamide-in-vitro
#10
Zhongbo Du, Luo Li, Wei Sun, Xiao Wang, Yao Zhang, Zhixiong Chen, Mengjuan Yuan, Zhen Quan, Nanjing Liu, Yanni Hao, Ting Li, Jinhua Wang, Chunli Luo, Xiaohou Wu
Castration-resistant prostate cancer (CRPC) continues to be a major challenge in the treatment of prostate cancer (PCa). The expression of hepatocyte cell adhesion molecule (HepaCAM), a novel tumor suppressor, is frequently downregulated or lost in PCa. Overactivated Notch signaling is involved in the development and progression of PCa, including CRPC. In this study, we found that the activities of Notch signaling were elevated, while HepaCAM expression was decreased in CRPC tissues compared with matched primary prostate cancer (PPC) tissues...
April 12, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29650929/-a-case-of-her2-positive-occult-breast-cancer-presenting-as-swollen-axillary-lymphnodes
#11
Toshiyuki Ishiba, Goshi Oda, Tsuyoshi Nakagawa, Takumi Akashi, Yamato Yamashita, Tomoki Aburatani, Taichi Ogo, Yutaka Nakashima, Hironobu Baba, Naoaki Hoshino, Yoshinobu Nishioka, Tatsuyuki Kawano
Occult breast cancer, which develops as a metastatic lesion with no primary tumor detected in the breast, is a rare breast cancer. A 68-year-old female patient particularly complained of the presence of a right axillary mass. The mass in the right axilla was palpable, but no tumor was found in both the breasts on palpation, ultrasound examination, or MRI. Partial breast resection and axillary lymph node dissection were performed following a diagnosis of invasive ductal carcinoma by core needle biopsy. There was no mammary gland tissue present around the tumor due to the pathology of the disease, and the tumor was diagnosed as occult breast cancer...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650858/-a-case-of-unresectable-advanced-gastric-cancer-treated-by-seven-courses-of-chemotherapy-with-docetaxel-cisplatin-and-s-1followed-by-conversion-surgery-achieved-five-year-relapse-free-survival
#12
Tetsushi Nakajima, Haruhiko Cho, Yoichiro Okubo, Kazuki Kano, Yukio Maezawa, Kousuke Ikeda, Takanobu Yamada, Takashi Ogata, Takaki Yoshikawa
The patient is a 51-year-old man.Upper gastrointestinal endoscopy revealed gigantic type 3 gastric cancer.Enhanced abdominal CT demonstrated a gigantic mass of 15×7 cm in the stomach, and a large number of peritoneal dissemination with moderate amount of ascites.The patient was diagnosed with cT4aN3bM1(peritoneal dissemination), Stage IV gastric cancer(JPN ver8)and was treated by chemotherapy with docetaxel(40mg/m / 2 day 1)plus cisplatin(60mg/m2 day 1)plus S-1(80mg/m2 day 1-14).After 7 courses of chemotherapy, peritoneal dissemination was disappeared...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650841/-a-case-of-advanced-esophageal-cancer-successfully-treated-with-multidisciplinary-therapy
#13
Junji Kawada, Masaya Nishino, Tomoki Hata, Takayuki Ogino, Masateru Okawa, Hiromitsu Hoshino, Miho Okano, Kenichi Nagai, Naruyasu Kakita, Yongkook Kim, Masaki Okuyama, Toshimasa Tsujinaka
We report a case of advanced esophageal cancer that was successfully treated using chemotherapy, operation, and chemoradiotherapy. A 66-year-old man with advanced esophageal cancer(Mt, O-Is, T4[N0.7-stomach], N2, M0, Stage III)was administered chemotherapy(docetaxel[DOC], cisplatin[CDDP], and 5-fluorouracil[5-FU]: DCF). As the esophageal tumor achieved complete clinical response after 2 courses of chemotherapy, lymph node dissection and proximal gastrectomy were performed for the residual tumor. Abdominal CT 3 months after surgery revealed lymph node swelling...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650393/-neoadjuvant-chemotherapy-with-concurrent-chemoradiotherapy-in-the-treatment-of-nasopharyngeal-cancer-southern-tunisian-experience
#14
Wafa Mnejja, Nabil Toumi, Nejla Fourati, Racem Bouzguenda, Abdelmonem Ghorbel, Mounir Frikha, Wicem Siala, Jamel Daoud
PURPOSE: A retrospective study to evaluate the efficacy and safety of the addition of neoadjuvant chemotherapy to concurrent chemoradiotherapy in the treatment of nasopharyngeal carcinoma. PATIENTS AND METHODS: Data from 62 patients treated for non-metastatic nasopharyngeal carcinoma were analyzed by comparing two groups of patients: a first group of 32 patients treated with 3 cycles of neoadjuvant chemotherapy based on docetaxel, cisplatin and 5-fluoro-uracil every 21 days followed by concurrent chemoradiotherapy (weekly cisplatin 40mg/m2 with radiotherapy 70Gy, 2Gy per session, 5 sessions per week) and a second group of 30 patients treated with the same concurrent chemoradiotherapy...
April 9, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29650387/tpf-induction-chemotherapy-followed-by-concurrent-chemoradiotherapy-for-locally-advanced-nasopharyngeal-carcinoma-long-term-results-of-a-tunisian-series
#15
N Toumi, W Ben Kridis, W Mnejja, R Bouzguenda, A Khanfir, A Ghorbel, J Daoud, M Frikha
PURPOSE: We represent in this study the long term results of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy in Tunisian patients with locally advanced nasopharyngeal carcinoma. The objective of our study is to analyse the efficacy as well as the toxicity of this therapeutic protocol. PATIENTS AND METHODS: Between January 2004 and December 2008, 32 patients with locoregional advanced non metastatic disease (T2b or above and/or N1 or above AJCC 2002) were treated in our institution by three cycles of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy every 21 days followed by concurrent chemoradiotherapy...
April 9, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/29649635/co-delivery-of-docetaxel-and-gemcitabine-by-anacardic-acid-modified-self-assembled-albumin-nanoparticles-for-effective-breast-cancer-management
#16
Varun Kushwah, Sameer S Katiyar, Chander Parkash Dora, Ashish Kumar Agrawal, Dimitrios A Lamprou, Ramesh C Gupta, Sanyog Jain
In the present study, we have modified bovine serum albumin (BSA) by covalently conjugating with anacardic acid (AA) and gemcitabine (GEM) and further used for development of docetaxel (DTX) loaded nanoparticles (AA-GEM-BSA NPs). AA is supposed to provide tumor targeting through VEGF receptors overexpressed in tumors, while the combination of GEM and DTX is supposed to provide synergistic activity by targeting multiple pathways. The conjugate was synthesized via carbodiimide chemistry and characterized by 1 H NMR, FTIR, MALDI-TOF and elemental analysis...
April 9, 2018: Acta Biomaterialia
https://www.readbyqxmd.com/read/29644451/emerging-therapies-in-metastatic-prostate-cancer
#17
REVIEW
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29642359/re-cabazitaxel-versus-docetaxel-as-first-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-a-randomized-phase-iii-trial-firstana
#18
https://www.readbyqxmd.com/read/29629866/prognostic-and-predictive-clinical-factors-in-patients-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#19
Daniel W Yokom, John Stewart, Nimira S Alimohamed, Eric Winquist, Scott Berry, Stacey Hubay, Jean-Baptiste Lattouf, Helene Leonard, Carla Girolametto, Fred Saad, Srikala S Sridhar
INTRODUCTION: Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel. METHODS: A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed...
April 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29629222/survival-benefit-of-perioperative-chemotherapy-in-patients-with-locally-advanced-gastric-cancer-a-propensity-score-matched-analysis
#20
Bang Wool Eom, Sohee Kim, Ja Yeon Kim, Hong Man Yoon, Mi-Jung Kim, Byung-Ho Nam, Young-Woo Kim, Young-Iee Park, Sook Ryun Park, Keun Won Ryu
Purpose: It has been reported that the survival of patients with locally advanced gastric cancer (LAGC) is better in East Asia countries than in developed western countries; however, the prognosis of LAGC remains poor. This study aimed to evaluate the effects of perioperative chemotherapy on the long-term survival of East Asia patients with LAGC. Materials and Methods: From October 2006 through August 2008, 43 patients with LAGC received perioperative S-1 combined with weekly docetaxel in a phase II study (neoadjuvant group)...
March 2018: Journal of Gastric Cancer
keyword
keyword
33993
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"